New AI-powered system promises to reduce inefficiencies in trial recruitment by automating eligibility prediction
New AI-powered system promises to reduce inefficiencies in trial recruitment by automating eligibility prediction
Clinical-stage companies AC Immune and Edgewise Therapeutics shared encouraging updates on their immunotherapy and cardiac medicine programs, signaling …
MaaT Pharma advances its microbiome ecosystem therapies with new preclinical evidence showing enhanced patient immunotherapy responses.
Experimental gene-silencing drug lepodisiran delivers long-lasting reduction of cardiovascular risk factor, while Spinogenix launches trial for novel synaptic …
Alnylam’s Fitusiran gains FDA approval as a first RNAi therapeutic for hemophilia, while Vertex discontinues its innovative insulin-producing …
The FDA approval of Alnylam’s Fitusiran marks a milestone in RNA interference therapeutics, while Vertex discontinues a novel …
MaaT Pharma strengthens financial position to advance its microbiome-based therapies, focusing on acute graft-versus-host disease and hemato-oncology indications.
Viking Therapeutics and Bluejay Therapeutics highlight progress in obesity management and neurological disease treatment with key clinical milestones.
Merck’s global license deal for HRS-5346 and Tiziana’s intranasal foralumab Phase 2 trial signify strides in cardiovascular and …
Abbott receives FDA approval to begin Phase 3 trial of its Intravascular Lithotripsy system aimed at improving outcomes …
Already a subscriber? Log in